Open AccessPolymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib
Author(s) -
Víctor Sapena,
M. Iavarone,
Loreto Boix,
F. Facchetti,
Maria Guarino,
Marco Sanduzzi Zamparelli,
Alessandro Granito,
Esther Samper,
Mario Scartozzi,
Josep Corominas,
Giorgia Marisi,
Alba Díaz,
Andrea CasadeiGardini,
Laura Gramantieri,
Pietro Lampertico,
Filomena Morisco,
Ferrán Torres,
Jordi Bruix,
María Reig
Publication year - 2022
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v14.i7.1438
Subject(s) - medicine , hepatocellular carcinoma , sorafenib , hazard ratio , cohort , single nucleotide polymorphism , confidence interval , oncology , adverse effect , liver cancer , proportional hazards model , genotype , pharmacology , gene , biology , genetics
Dermatologic adverse events (DAEs) are associated with a better outcome in patients with hepatocellular carcinoma (HCC) irrespective of the therapeutic agent received. The exact mechanisms associated with the development of DAEs are unknown although several studies point to direct toxicity of tyrosine kinase inhibitors (TKIs) to the skin or an immune-mediated reaction triggered by the oncologic treatment. As is the case in other conditions, individual genetic variants may partially explain a higher risk of DAEs.